Shenzhen Zhongge Biotechnology Co. Ltd. has disclosed translation initiation factor 2B (eIF2B) activators reported to be useful for the treatment of viral infections, inflammation, cancer, neurodegeneration, and autoimmune, eye, renal and dermatological disorders, among others.
Enanta Pharmaceuticals Inc. has divulged macrocyclic chalcone-amide compounds acting as non-structural protein 3 (nsp3; PL-pro) (SARS-CoV-2; COVID-19 virus) inhibitors.
McGill University, Université de Montreal, Yeda Research and Development Co. Ltd. and Yissum Research Development Co. have jointly developed anisomycin analogues reported to be useful for the treatment of giardiasis, leishmaniasis, toxoplasmosis and trypanosomiasis.
At last week’s EASL meeting, Janssen Pharmaceutica NV disclosed the discovery and preclinical evaluation of a novel pan-genotypic hepatitis E virus (HEV) replication inhibitor, JNJ-64779117 (JNJ-9117).
SA-012 is an N-acetylgalactosamine (GalNAc) conjugated silencing RNA (siRNA) that targets the mRNA of the PD-L1 gene and is being developed by Suzhou Siran Biotechnology Co. Ltd. for the treatment of chronic hepatitis B (CHB).
Schrodinger Inc. and Takeda Pharmaceutical Co. Ltd. have identified 3C-like proteinase (3CLpro; Mpro; nsp5) inhibitors reported to be useful for the treatment of coronavirus acute respiratory syndrome.
SA-012 is an N-acetylgalactosamine (GalNAc) conjugated silencing RNA (siRNA) that targets the mRNA of the PD-L1 gene and is being developed by Suzhou Siran Biotechnology Co. Ltd. for the treatment of chronic hepatitis B (CHB).
Rome Therapeutics Inc. has synthesized cyclopentene-oxymethylene phosphonamidate compounds acting as LINE-1 retrotransposable element ORF1 protein (L1RE1) and/or HERV-K reverse transcriptase inhibitors.
Previous studies have found that the effectiveness of vaccines can be increased with the knockdown of HBsAg using a small interfering RNA (siRNA). The efficacy of a bivalent mRNA vaccine in combination with the siRNA AD-66810, which targets the X gene expression in the hepatitis B virus (HBV) genome, was tested in a murine model of AAV/HBV by scientists from Clearb Therapeutics Inc.
RSS